-

Stimwave Technologies and Aspen Medical Products Partner to Enhance Patient Satisfaction Through the Development of Wearable Pain Management Solutions

POMPANO BEACH, Fla. & IRVINE, Calif.--(BUSINESS WIRE)--Stimwave Technologies (Stimwave), the manufacturer of the Freedom Spinal Cord Stimulator (SCS) System, and Aspen Medical Products (Aspen), the industry leader in solutions for pain and mobility management, today announced a collaboration to develop an innovative wearable pain management accessory for Stimwave’s patients suffering from chronic pain.

“We are constantly looking for ways to improve our therapies' patient and physician experience. The ability for a chronic pain patient to actively participate in their care, alongside their doctor is a critical component in improving their quality of life,” said Aure Bruneau, Stimwave’s Chief Executive Officer. “Our HF-EMC power transfer technology gives us a unique opportunity to combine our system with Aspen’s deep design experience that millions of patients and clinicians have trusted for decades. Together, we can now provide an improved patient-specific solution. We are also committed to leading in the development of additional therapy options that combine bracing and neuromodulation to deliver the next generation of chronic pain management.”

Stimwave’s Freedom SCS platform is designed to treat chronic pain typically associated with a patient’s back and legs by stimulating nerves along their spine. Unlike other neurostimulator devices on the market, Stimwave’s Freedom SCS therapy is powered wirelessly. To continue to enhance the patient experience with the platform, Stimwave and Aspen have partnered to develop a wearable that comfortably and securely houses the systems’ external components. The new wearable can be worn under clothing, allowing for simplified, discreet, and uninterrupted treatment.

“This partnership allows us to leverage Stimwave and Aspen’s combined capabilities into one elegant and concise system that helps patients suffering from chronic pain get back to their normal lives faster,” commented Jim Cloar, Aspen’s Chief Executive Officer. “Central to everything we do is the necessity to be a significant part of the puzzle of treating pain and changing lives for the better. We are continually focused on delivering the highest-quality products and solutions that enable pain relief and promote mobility.”

Clinicians are invited to visit the Stimwave booth (#303) or the Aspen booth (#404) at ASIPP (American Society of Interventional Pain Physicians) May 5-7, 2022 in Las Vegas to find out more. Additionally, please visit www.StimwaveFreedom.com to contact a representative.

About Stimwave

Stimwave Technologies Incorporated is a privately held medical device company engaged in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management. www.stimwavefreedom.com

About Aspen Medical Products

Founded in 1994, Aspen Medical Products, LLC is the industry leader in the development and manufacturing of spinal orthopedics and pain therapy solutions. Designed to restore function and alleviate pain, Aspen’s products address a variety of patient needs across the continuum of care to help them resume activities of daily living. Headquartered in Irvine, California, Aspen has local sales representation throughout the U.S. and internationally. www.aspenmp.com

Contacts

Investors:
Mike Vallie
ICR Westwicke
mike.vallie@westwicke.com

Stimwave Technologies and Aspen Medical Products


Release Versions

Contacts

Investors:
Mike Vallie
ICR Westwicke
mike.vallie@westwicke.com

More News From Stimwave Technologies and Aspen Medical Products

Stimwave Announces Sale of Business

POMPANO BEACH, Fla.--(BUSINESS WIRE)--Stimwave Technologies Incorporated and its subsidiary, Stimwave LLC (collectively, “Stimwave” or the “Company”), a leading provider of neurostimulation devices offering chronic pain relief, announced today that it has reached an agreement to sell substantially all of its assets to Kennedy Lewis Management LP or its affiliate (“Kennedy Lewis”). Since 2020, the Company has successfully re-structured its entire team and business operations. The new Stimwave te...

Stimwave Technologies Launches FREEDOM-1 Clinical Trial for Peripheral Nerve Stimulation to Treat Chronic Knee Pain

POMPANO BEACH, Fla.--(BUSINESS WIRE)--Today, Stimwave Technologies announced the level-1 FREEDOM clinical trial series launch. The FREEDOM clinical trial series consists of multi-center, prospective, randomized trials that monitor chronic pain patients’ responses to peripheral nerve stimulation (PNS) over time. Leading through the investment of level-1 evidence-based data in PNS is a central part of Stimwave’s ongoing commitment to outstanding outcomes for treating patients suffering from chron...

Stimwave Technologies Receives Reimbursement Authorization in Germany

POMPANO BEACH, Fla.--(BUSINESS WIRE)--Today Stimwave Technologies announced that it has received additional reimbursement authorization in Germany, one of the Company’s largest commercial markets outside of the United States. The German Institute for Hospital Remuneration (InEK) has granted Stimwave Technologies’ Freedom PNS and SCS products Status 1 designation under its NUB funding process. Being designated NUB Status 1 entitles hospitals in Germany that submitted a NUB application to negotia...
Back to Newsroom